Sherlock Biosciences and Dartmouth-Hitchcock Health (D-HH) will study Sherlock's CRISPR SARS-CoV-2 kit, which recently received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA).
The kit will be used to better understand how it may help avoid some of the challenges associated with real-time polymerase chain reaction (PCR) testing.
Sherlock's kit will be used to test clinical samples from Dartmouth-Hitchcock facilities. It is the first and only CRISPR-based diagnostic test to receive EUA from the FDA for qualitative detection of nucleic acid from SARS-CoV-2.
